That’s a Theory, but it’s flawed. LP’s goal is to bring DCVax-L to the market. Advent was used to develop protocols and is licensed now to import tissue and export the vaccine for compassionate care. Advent is currently being used to set up protocols for the latest version of Flaskworks. After the protocols have been hammered out with Flaskworks v2.0, DCVax-L will be submitted and approved in the US. Needless to say, LP has had to maintain control over the production process.
Market Data 
Markets 
AI
